U L Medicines Limited

POWER SEARCH PRICING

SOLUTIONS

u l medicines limited Company Information

Company Number

06120521

Next Accounts

2 days late

Directors

Richard Paling

Jerome Charton

Shareholders

clinigen pharma limited

Group Structure

View All

Industry

Dormant Company

Registered Address

25 bedford square, bloomsbury, london, WC1B 3HH

Website

https://www.clinigengroup.com

u l medicines limited Estimated Valuation

£273.2k

Pomanda estimates the enterprise value of U L MEDICINES LIMITED at £273.2k based on Net Assets of £506k and 0.54x industry multiple (adjusted for liquidity).

Edit your figures and get a professional valuation report.

U L Medicines Limited is a live company located in london, WC1B 3HH with a Companies House number of 06120521. It operates in the dormant company sector, SIC Code 99999. Founded in February 2007, it's largest shareholder is clinigen pharma limited with a 100% stake. U L Medicines Limited is a established, unknown sized company, Pomanda has estimated its turnover at £0 with declining growth in recent years.

View Sample

Upgrade for unlimited company reports & a free credit check

Pomanda's financial health check has awarded U L Medicines Limited a 1 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 2 areas for improvement. Company Health Check FAQs

Health Rating1out of 5

1 Strong

0 Regular

2 Weak

Size

There is insufficient data available for this Key Performance Indicator!

Growth

3 year (CAGR) sales growth of -100%, show it is growing at a slower rate (4.5%)

EXPORT

U L Medicines Limited's latest turnover from June 2023 is 0 and the company has net assets of £506 thousand. According to their latest financial statements, we estimate that U L Medicines Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.

Data source: Companies House, Pomanda Estimates

	Jun 2023	Jun 2022	Jun 2021	Jun 2020	Jun 2019	Jun 2018	Jan 2017	Jan 2016	Jan 2015	Jan 2014	Jan 2013	Jul 2011	Jul 2010	Jul 2009
Turnover			31,761	2,621,411	9,437,693	15,396,798	11,126,257	11,268,206	8,555,512	7,860,127	11,569,952	5,489,618	3,470,797
Other Income Or Grants
Cost Of Sales			16,004	1,888,143	6,268,585	11,165,039	8,066,771	7,658,849	5,732,198	5,301,834	7,775,945	3,085,689	2,980,015
Gross Profit			15,757	733,268	3,169,108	4,231,759	3,059,486	3,609,357	2,823,314	2,558,293	3,794,007	2,403,929	490,781
Admin Expenses		241	-56,845	457,193	1,332,849	2,234,934	1,476,690	1,188,298	1,050,364	1,032,543	1,868,066	451,150	64,800	-617,357
Operating Profit		-241	72,602	276,075	1,836,259	1,996,825	1,582,796	2,421,059	1,772,950	1,525,750	1,925,941	1,952,779	425,981	617,357
Interest Payable				123	4	96
Interest Receivable									146		40		760	272
Pre-Tax Profit		-241	72,602	275,952	1,836,255	1,996,729	1,582,796	2,421,059	1,773,096	1,525,750	1,925,981	1,952,779	426,740	617,629
Tax			-13,890	-50,595	-346,354	-388,139	-319,139	-486,272	-385,331	-344,776	-481,487	-533,960	-119,487	-172,936
Profit After Tax		-241	58,712	225,357	1,489,901	1,608,590	1,263,657	1,934,787	1,387,765	1,180,974	1,444,494	1,418,819	307,253	444,693
Dividends Paid										1,300,000	46,250	270,500
Retained Profit		-241	58,712	225,357	1,489,901	1,608,590	1,263,657	1,934,787	1,387,765	-119,026	1,398,244	1,148,319	307,253	444,693
Employee Costs				148,918	631,840	1,520,217	1,084,808	937,688	823,492	764,832	857,803	250,990	340,382
Number Of Employees	1	1	1	9	18	23	23	22	18	16	14	5	12
EBITDA*		-241	95,518	300,318	1,863,126	2,039,277	1,637,127	2,480,739	1,832,630	1,557,617	1,929,776	1,952,779	434,731	626,107

* Earnings Before Interest, Tax, Depreciation and Amortisation

	Jun 2023	Jun 2022	Jun 2021	Jun 2020	Jun 2019	Jun 2018	Jan 2017	Jan 2016	Jan 2015	Jan 2014	Jan 2013	Jul 2011	Jul 2010	Jul 2009
Tangible Assets				17,412	32,222	15,436	15,652	21,242	55,888	115,568	21,608			26,250
Intangible Assets				5,504	14,937	24,370	138,318	179,272	41,646
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets				22,916	47,159	39,806	153,970	200,514	97,534	115,568	21,608			26,250
Stock & work in progress					669,612	660,596	1,149,066	1,188,078	1,042,799	924,436	722,678	447,145	379,717	166,852
Trade Debtors				1,157,823	901,725	1,080,515	1,052,438	1,278,645	1,124,126	681,026	832,805	1,277,806	850,702	689,331
Group Debtors	595,564	595,564	556,365	10,124,198	10,060,971	8,307,619	6,586,865	4,481,083	3,065,600	1,644,538	2,149,884
Misc Debtors				25,128	31,657	43,111	301,793	419,650	298,894	39,719	7,112	355,100
Cash			42,223	122,907	777,322	752,820	451,873	875,976	690,678	917,814	601,335	610,415	195,114	108,703
misc current assets
total current assets	595,564	595,564	598,588	11,430,056	12,441,287	10,844,661	9,542,035	8,243,432	6,222,097	4,207,533	4,313,814	2,690,466	1,425,533	964,886
total assets	595,564	595,564	598,588	11,452,972	12,488,446	10,884,467	9,696,005	8,443,946	6,319,631	4,323,101	4,335,422	2,690,466	1,425,533	991,136
Bank overdraft
Bank loan
Trade Creditors				73,898	396,613	619,116	522,342	665,201	301,432	347,660	541,525	349,043	673,487	546,343
Group/Directors Accounts	89,611	89,611	89,611	89,611	406,153	392,589	584,929	624,508	768,195	301,006	6,116
other short term finances
hp & lease commitments
other current liabilities			2,783	102,440	724,014	400,997	763,829	637,440	677,551	494,852	489,172	441,058
total current liabilities	89,611	89,611	92,394	265,949	1,526,780	1,412,702	1,871,100	1,927,149	1,747,178	1,143,518	1,036,813	790,101	673,487	546,343
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
total long term liabilities
total liabilities	89,611	89,611	92,394	265,949	1,526,780	1,412,702	1,871,100	1,927,149	1,747,178	1,143,518	1,036,813	790,101	673,487	546,343
net assets	505,953	505,953	506,194	11,187,023	10,961,666	9,471,765	7,824,905	6,516,797	4,572,453	3,179,583	3,298,609	1,900,365	752,046	444,793
total shareholders funds	505,953	505,953	506,194	11,187,023	10,961,666	9,471,765	7,824,905	6,516,797	4,572,453	3,179,583	3,298,609	1,900,365	752,046	444,793

	Jun 2022	Jun 2021	Jun 2020	Jun 2019	Jun 2018	Jan 2017	Jan 2016	Jan 2015	Jan 2014	Jan 2013	Jul 2011	Jul 2010	Jul 2009
Operating Activities
Operating Profit	-241	72,602	276,075	1,836,259	1,996,825	1,582,796	2,421,059	1,772,950	1,525,750	1,925,941	1,952,779	425,981	617,357
Depreciation		17,412	14,810	17,434	9,927	19,350	59,680	59,680	31,867	3,835		8,750	8,750
Amortisation		5,504	9,433	9,433	32,525	34,981
Tax		-13,890	-50,595	-346,354	-388,139	-319,139	-486,272	-385,331	-344,776	-481,487	-533,960	-119,487	-172,936
Stock			-669,612	9,016	-488,470	-39,012	145,279	118,363	201,758	722,678	67,428	212,865	166,852
Debtors	39,199	-10,750,784	312,796	1,563,108	1,490,149	1,761,718	1,690,758	2,123,337	-624,518	2,989,801	782,204	161,371	689,331
Creditors		-73,898	-322,715	-222,503	96,774	-142,859	363,769	-46,228	-193,865	541,525	-324,444	127,144	546,343
Accruals and Deferred Income	-2,783	-99,657	-621,574	323,017	-362,832	126,389	-40,111	182,699	5,680	489,172	441,058
Deferred Taxes & Provisions
Cash flow from operations	-42,223	10,658,857	-337,750	45,162	383,401	-421,188	482,088	-657,930	1,447,416	-1,233,493	685,801	68,152	143,331
Investing Activities
capital expenditure				-34,220	71,712	-7,787	-162,660	-41,646	-125,827	-25,443		17,500	-35,000
Change in Investments
cash flow from investments				-34,220	71,712	-7,787	-162,660	-41,646	-125,827	-25,443		17,500	-35,000
Financing Activities
Bank loans
Group/Directors Accounts			-316,542	13,564	-192,340	-39,579	-143,687	467,189	294,890	6,116
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue		-10,739,541			38,270	44,451	9,557	5,105		1,900,365			100
interest			-123	-4	-96			146		40		760	272
cash flow from financing		-10,739,541	-316,665	13,560	-154,166	4,872	-134,130	472,440	294,890	1,906,521		760	372
cash and cash equivalents
cash	-42,223	-80,684	-654,415	24,502	300,947	-424,103	185,298	-227,136	316,479	601,335	415,301	86,411	108,703
overdraft
change in cash	-42,223	-80,684	-654,415	24,502	300,947	-424,103	185,298	-227,136	316,479	601,335	415,301	86,411	108,703

Very Low Risk70 - 100

Low Risk50 - 70

Moderate Risk30 - 50

High Risk20 - 30

Very High Risk0 - 20

Get a comprehensive credit check for u l medicines limited. Get real-time insights into u l medicines limited's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Perform a competitor analysis for u l medicines limited by selecting its closest rivals, whether from the ACTIVITIES OF EXTRATERRITORIAL ORGANISATIONS AND BODIES sector, other established companies, companies in WC1B area or any other competitors across 12 key performance metrics.

U L MEDICINES LIMITED group structure

U L Medicines Limited has no subsidiary companies.

Ultimate parent company

TRILEY HOLDCO LTD

#0139690

CLINIGEN PHARMA LIMITED

07248508

2 parents

U L MEDICINES LIMITED

06120521

U L MEDICINES LIMITED Shareholders

clinigen pharma limited

100%

U L Medicines Limited currently has 2 directors. The longest serving directors include Mr Richard Paling (Mar 2019) and Mr Jerome Charton (Apr 2024).

officer	country	age	start	end	role
Mr Richard Paling	United Kingdom	54 years	Mar 2019	-	Director
Mr Jerome Charton	England	60 years	Apr 2024	-	Director

P&L

June 2023

turnover

operating profit

-100%

gross margin

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

June 2023

net assets

506k

total assets

595.6k

cash

net assets

Total assets minus all liabilities

Similar Companies

autumn healthcare limited

c.d. medical limited

4.5

mardalina (uk) ltd

blackbird pharmacy limited

4.5

dakota pharma limited

company number

06120521

Type

Private limited with Share Capital

industry

99999 - Dormant Company

incorporation date

February 2007

ultimate parent company

TRILEY HOLDCO LTD

previous names

N/A

address

25 bedford square, bloomsbury, london, WC1B 3HH

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We did not find charges/mortgages relating to u l medicines limited.

When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.

Click to start generating capital raising & share issue transactions for U L MEDICINES LIMITED. This can take several minutes, an email will notify you when this has completed.

u l medicines limited Company Information

u l medicines limited Estimated Valuation

u l medicines limited Estimated Valuation

u l medicines limited Estimated Valuation

U L Medicines Limited Overview

U L Medicines Limited Health Check

U L MEDICINES LIMITED financials

u l medicines limited Credit Report and Business Information

U L Medicines Limited Competitor Analysis

u l medicines limited Ownership

u l medicines limited directors

u l medicines limited company details

u l medicines limited Charges & Mortgages

u l medicines limited Capital Raised & Share Issues BETA

u l medicines limited Companies House Filings - See Documents